Cardiotoxicity Associated with the Tyrosine Kinase Inhibitor Sunitinib

BACKGROUND: Tyrosine kinase inhibitors (TKIs) have advanced cancer treatment. Sunitinib, a recently-approved, multi-targeted TKI, prolongs survival for patients with metastatic renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST), but concerns about cardiac safety have arisen with th...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Chu, Tammy F., Rupnick, Maria A., Kerkela, Risto, Dallabrida, Susan M., Zurakowski, David, Nguyen, Lisa, Woulfe, Kathleen, Pravda, Elke, Cassiola, Flavia, Desai, Jayesh, George, Suzanne, Morgan, Jeffrey A., Harris, David, Ismail, Nesreen S., Chen, Jey-Hsin, Schoen, Frederick J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2007
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2643085/
https://ncbi.nlm.nih.gov/pubmed/18083403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(07)61865-0
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller